CYTK - Cytokinetics, Incorporated
NEXT EARNINGS:
Feb 24, 2026
(today)
EPS Est: $-1.48
|
Rev Est: $8.0M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$91.58
DETAILS
HIGH:
$136.00
LOW:
$61.00
MEDIAN:
$90.00
CONSENSUS:
$91.58
UPSIDE:
30.64%
Market Cap:
8.57B
Volume:
1,938,428
Avg Volume:
1,856,258
52 Week Range:
29.31-70.98
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.55
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
498
IPO Date:
2004-04-30
EPS (TTM):
-5.26
P/E Ratio:
-8.94
Revenue (TTM):
18.47M
Total Assets:
1.40B
Total Debt:
788.68M
Cash & Equiv:
94.86M
Rev Growth (5Y):
-7.2%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-41.2%
Debt/Equity:
-5.83
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-1.54 | $-1.59 | +3.1% | $1.9M | $8.0M | -75.9% |
| 2025-08-07 | $-1.12 | $-1.34 | +16.4% | $66.8M | $2.1M | +3131.1% |
| 2025-05-06 | $-1.36 | $-1.41 | +3.5% | $1.6M | $2.8M | -43.4% |
| 2025-02-27 | $-1.26 | $-1.29 | +2.3% | $16.9M | $14.3M | +18.7% |
| 2024-11-06 | $-1.36 | $-1.27 | -7.1% | $463000 | $2.0M | -77.4% |
| 2024-08-08 | $-1.31 | $-1.02 | -28.4% | $249000 | $920000 | -72.9% |
| 2024-05-08 | $-1.33 | $-1.16 | -14.7% | $835000 | $900000 | -7.2% |
| 2024-02-27 | $-1.38 | $-1.03 | -34.0% | $1.7M | $10.8M | -84.5% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.47M | 7.53M | 94.59M | 70.43M | 55.83M | 26.87M | 31.50M | 13.37M | 106.41M | 28.66M | 46.94M | 30.65M |
| Net Income | (589.53M) | (526.24M) | (388.95M) | (215.31M) | (127.29M) | (121.69M) | (106.29M) | (127.79M) | 16.45M | (37.50M) | (14.65M) | (33.72M) |
| EPS | -5.26 | -5.45 | -4.33 | -2.80 | -1.97 | -2.59 | -1.95 | -2.59 | 0.41 | -0.97 | -0.41 | -1.24 |
| Total Assets | 1.40B | 824.32M | 1.01B | 841.32M | 533.80M | 289.81M | 211.18M | 294.81M | 170.14M | 115.24M | 132.97M | 83.19M |
| Total Debt | 788.68M | 755.77M | 750.30M | 269.93M | 138.94M | 136.07M | 42.41M | 31.78M | 27.38M | 14.64M | 0 | 0 |
| Cash & Equivalents | 94.86M | 113.02M | 65.58M | 112.67M | 82.98M | 36.43M | 42.26M | 125.21M | 66.87M | 65.08M | 20.21M | 20.16M |
| Operating Cash Flow | (395.89M) | (414.33M) | (299.52M) | (142.52M) | 8.94M | (90.91M) | (101.22M) | (101.76M) | 36.98M | 4.88M | (44.84M) | (7.72M) |
| Free Cash Flow | (399.80M) | (415.75M) | (310.85M) | (191.39M) | (2.11M) | (93.53M) | (102.10M) | (104.64M) | 35.39M | 4.32M | (45.95M) | (8.26M) |
| FCF per Share | -3.57 | -4.31 | -3.46 | -2.49 | -0.03 | -1.62 | -1.88 | -2.12 | 0.89 | 0.11 | -1.29 | -0.30 |
| Book Value | (135.37M) | (386.32M) | (107.90M) | 243.86M | 113.38M | (10.94M) | 25.93M | 109.84M | 94.36M | 68.59M | 92.06M | 54.44M |
| Cash & ST Investments | 1.08B | 614.82M | 782.58M | 471.64M | 464.06M | 225.11M | 198.73M | 268.89M | 156.25M | 111.44M | 83.23M | 77.73M |
| ROC Equity | N/A | N/A | N/A | -0.88 | -1.12 | N/A | -4.10 | -1.16 | 0.17 | -0.55 | -0.16 | -0.62 |